Role of bisphosphonates in osteoporosis
- At: 2004 FIP Congress in New Orleans (USA)
- Type: Presentation
- By: ROSEN, Clifford (St. Joseph Hospital, Maine Center for Osteoporosis Research, Bangor, United States of America)
Bisphosphonates, have revolutionized the treatment of metabolic bone diseases. Etidronate was a first generation agent used to treat heterotopic ossification and Paget’s disease. Its availability prompted off label use of this drug for osteoporosis. Trials have shown that etidronate increases BMD and reduces spine fractures. Alendronate was the.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.